Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) frequently presents with dysfunction or loss of the sense of smell, resulting in a signifcant impairment in quality of life. The medical treatments currently available may improve the olfactory function in patients with CRSwNP, but such an outcome is generally only transitory. We report the case of a patient with CRSwNP who completely recovered from smell sense loss by treatment with mepolizumab. Case presentation: The patient was a 62-year-old female who has severe asthma induced by allergy to Dermatophagoides and concomitant CRSwNP. Any treatment for the latter, including oral and injective corticosteroids, was unsuccessful in the loss of smell. Due to the satisfaction of admission criteria to mepolizumab treatment for severe asthma, treatment was initiated on March 2018, resulting in good clinical control of both asthma and CRSwNP, and particularly in complete recovery of the smell loss after 4 months of treatment and still persisting. Conclusion: In this case report, the treatment with mepolizumab in a patient allergic to Dermatophagoides and afected by CRSwNP was associated with an improvement of anosmia. That fnding may be explained by a reduction of the nasal obstruction by nasal polyps

Recovery of smell sense loss by mepolizumab in a patient allergic to dermatophagoides and affected by chronic rhinosinusitis with nasal polyps / Cavaliere, Carlo; Incorvaia, Cristoforo; Frati, Franco; Messineo, Daniela; Ciotti, Mario; Greco, Antonio; de Vincentiis, Marco; Masieri, Simonetta. - In: CLINICAL AND MOLECULAR ALLERGY. - ISSN 1476-7961. - 17:3(2019). [10.1186/s12948-019-0106-2]

Recovery of smell sense loss by mepolizumab in a patient allergic to dermatophagoides and affected by chronic rhinosinusitis with nasal polyps

Cavaliere, Carlo
Primo
;
Messineo, Daniela;Ciotti, Mario;Greco, Antonio;de Vincentiis, Marco
Penultimo
;
Masieri, Simonetta
Ultimo
2019

Abstract

Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) frequently presents with dysfunction or loss of the sense of smell, resulting in a signifcant impairment in quality of life. The medical treatments currently available may improve the olfactory function in patients with CRSwNP, but such an outcome is generally only transitory. We report the case of a patient with CRSwNP who completely recovered from smell sense loss by treatment with mepolizumab. Case presentation: The patient was a 62-year-old female who has severe asthma induced by allergy to Dermatophagoides and concomitant CRSwNP. Any treatment for the latter, including oral and injective corticosteroids, was unsuccessful in the loss of smell. Due to the satisfaction of admission criteria to mepolizumab treatment for severe asthma, treatment was initiated on March 2018, resulting in good clinical control of both asthma and CRSwNP, and particularly in complete recovery of the smell loss after 4 months of treatment and still persisting. Conclusion: In this case report, the treatment with mepolizumab in a patient allergic to Dermatophagoides and afected by CRSwNP was associated with an improvement of anosmia. That fnding may be explained by a reduction of the nasal obstruction by nasal polyps
2019
chronic rhinosinusitis with nasal polyps; smell sense loss; eosinophilic; mepolizumab
01 Pubblicazione su rivista::01i Case report
Recovery of smell sense loss by mepolizumab in a patient allergic to dermatophagoides and affected by chronic rhinosinusitis with nasal polyps / Cavaliere, Carlo; Incorvaia, Cristoforo; Frati, Franco; Messineo, Daniela; Ciotti, Mario; Greco, Antonio; de Vincentiis, Marco; Masieri, Simonetta. - In: CLINICAL AND MOLECULAR ALLERGY. - ISSN 1476-7961. - 17:3(2019). [10.1186/s12948-019-0106-2]
File allegati a questo prodotto
File Dimensione Formato  
Cavaliere_Recovery of smell_2019.pdf

accesso aperto

Note: https://clinicalmolecularallergy.biomedcentral.com/articles/10.1186/s12948-019-0106-2
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 756.42 kB
Formato Adobe PDF
756.42 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1230202
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 11
  • ???jsp.display-item.citation.isi??? ND
social impact